Datavant takes step towards goal of doubling clinical trials success rate

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/solarseven)
(Image: Getty/solarseven)

Related tags Clinical trial data Clinical trial

Datavant has integrated its 150th dataset through a partnership that will “transform” the drug development process, says co-founder.

The San Francisco-based healthcare technology company has named Duke Clinical Research Institute (DCRI) as its Founding Academic Partner, marking integration of its 150th​ dataset, which includes clinical trial data, claims data, pharmacy data, electronic health records, and genomics, among others.

The combination of DCRI’s analytic expertise and proprietary datasets, with Datavant's reach and data integration capabilities, sets the foundation for a partnership “that will transform the process of drug development​,” said Datavant President and Co-Founder Travis May.

DCRI will work with Datavant to implement clinical trial design that leverages combined datasets and analytics, according to the company – as it aims to reach its goal of doubling the success rate of drugs entering clinical trials by 2020.

When asked how he proposes to meet this objective, May told us Datavant is able to offer a broader set of insights to clinical trialists and “ensure that good assets don't fall through the cracks​” through integrating clinical trial data with real-world datasets.

While many investigational drugs fail due to inherent shortcomings in safety and efficacy, for many promising medicines it's instead a failure of matching the right dose to the right set of patients and designing a trial that demonstrates separation of signal from noise​,” he said.

Datavant has initiated a number of pilot programs with pharmaceutical partners through which it will “generate invaluable learnings to further augment the insights our product delivers​,” said May.

In the upcoming months, he said the company is focused on executing these pilot efforts, expanding its data partner network, and bringing additional talent to its team.

 “The problem that we aim to solve will require the collective action of a network of healthcare stakeholders​,” said May, “and we are always eager to partner with like-minded players in the space to bring much-needed transformation to the industry​.”

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us


View more